Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer

• Published in: Ėksperimental'nai͡a︡ i klinicheskai͡a︡ gastroėnterologii͡a no. 4; p. 86
• Main Authors: Serebrova, S Iu, Starodubtsev, A K, Pisarev, V V, Kondratenko, S N, Vasilenko, G F, Dobrovol'skiĭ, O V
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2009
• Subjects: Adult; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - pharmacokinetics; Anti-Ulcer Agents - pharmacology; Anti-Ulcer Agents - therapeutic use; Biological Availability; Duodenal Ulcer - drug therapy; Duodenal Ulcer - metabolism; Esomeprazole; Female; Gastric Acid - secretion; Gastric Acidity Determination; Humans; Male; Omeprazole - administration & dosage; Omeprazole - pharmacokinetics; Omeprazole - pharmacology; Omeprazole - therapeutic use; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - pharmacokinetics; Proton Pump Inhibitors - pharmacology; Proton Pump Inhibitors - therapeutic use; Time Factors; Tissue Distribution
• ISSN: 1682-8658

There were authentic distinctions between the groups of healthy volunteers and patients with a peptic ulcer disease in Cmax, Tmax, AUC(0-t), AUC(0-infinity), CIt, Vd of omeprazole and Cmax of esomeprazole (Nexium, AstraZeneca). When the pharmacokinetics of omeprazole and ezomeprazole were compared in both groups, there were authentic distinctions in Cmax, AU(0-t), AUC(0-infinity), CIt, T1/2. The patients who had taken omeprazole the time of hypoacide condition was much shorter than in other groups. Disintegration test modeling pHmax for pH oscillation with large amplitude, that is typical for ulcer disease, demonstrated a possibility of early partial release of omeprazole, its acid-depended degradation and reduction of its bioavailability.